Financhill
Back

UroGen Pharma Quote, Financials, Valuation and Earnings

UroGen Pharma Price Quote

$10.66
-0.01 (-0.47%)
(Updated: December 21, 2024 at 5:52 AM ET)

UroGen Pharma Key Stats

Sell
22
UroGen Pharma (URGN) is a Sell

Day range:
$10.51 - $11.08
52-week range:
$10.51 - $20.70
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
4.46
P/B ratio:
17.65%

Volume:
1.4M
Avg. volume:
418.8K
1-year change:
-28.24%
Market cap:
$450.3M
Revenue:
$82.7M
EPS:
$-3.09

How Much Does UroGen Pharma Make?

Data Unavailable

Is UroGen Pharma Growing As A Company?

Data Unavailable

UroGen Pharma Stock Price Performance

  • Did UroGen Pharma Stock Go Up Last Month?
    UroGen Pharma share price went down by -6.81% last month
  • Did URGN's Share Price Rise Over The Last Year?
    URGN share price fell by -28.24% over the past 1 year

What Is UroGen Pharma 52-Week High & Low?

UroGen Pharma Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy UroGen Pharma?

Data Unavailable

Is UroGen Pharma Cash Flow Positive?

Data Unavailable

UroGen Pharma Return On Invested Capital

Data Unavailable

UroGen Pharma Earnings Date & Stock Price

  • What Is UroGen Pharma's Stock Price Today?
    A single share of URGN can be purchased today for 10.67
  • What Is UroGen Pharma’s Stock Symbol?
    UroGen Pharma trades on the nasdaq under the ticker symbol: URGN
  • When Is UroGen Pharma’s Next Earnings Date?
    The next quarterly earnings date for UroGen Pharma is scheduled on March 14, 2025
  • When Is URGN's next ex-dividend date?
    UroGen Pharma's next ex-dividend date is December 21, 2024
  • How To Buy UroGen Pharma Stock?
    You can buy UroGen Pharma shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.

UroGen Pharma Competitors

  • Who Are UroGen Pharma's Competitors?
    Below is a list of companies who compete with UroGen Pharma or are related in some way:
    • Arbutus Biopharma Corp (ABUS)
    • Amicus Therapeutics Inc (FOLD)
    • Ionis Pharmaceuticals Inc (IONS)
    • Lantheus Holdings Inc (LNTH)
    • Royalty Pharma PLC (RPRX)

UroGen Pharma Dividend Yield

Data Unavailable

UroGen Pharma Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 32.69%
Revenue: 20.87% 4.13%

Analyst Recommendations

Buy Recommendations: 3
Hold Recommendations: 1
Sell Recommendations: 0
Price Target: 38.50
Upside from Last Price: 260.82%

Major Shareholders

Data Unavailable